Crosstalk between glucagon
On the other hand, the mechanism of action of GLP-1 on gut microbiota involves the inflammatory response . Additionally, we discuss the effects and mechanism of various interventions, such as prebiotics, probiotics, antidiabetic drugs, and bariatric surgery, on the crosstalk between gut microbiota and GLP-1 .
This review examines how GLP-1 receptor agonists and the gut microbiome influence one another through bile acid signaling, short-chain fatty acids, and inflammatory pathways. It explores how ...
The impact of GLP-1 medications on the gut microbiota, which is partly mediated by gut IELs, may also affect the intestinal response to inflammation and its interaction with the host immune system, warranting further investigation.
Glucagon-like peptide-1 receptor agonists ( GLP -1RAs) are a class of agents where use has surged in recent years, with global sales projected to reach $100 billion by 2030. 3 Originally developed for glycemic control and weight loss, GLP -1RAs are now attracting attention for their potential anti- inflammatory , immunomodulatory, and gut barrier ...

Useful Notes on Glp-1 And Gut Inflammatory Response
2 GLP-1 : a key player in metabolic homeostasis GLP-1 is a 31 aminoacid-long peptide derived from proglucagon ( 15 ), which is produced in response to both nutritional and inflammatory stimuli. It is mainly produced by enteroendocrine L-cells, which are distributed throughout the gastrointestinal tract, with increasing density from the proximal jejunum to the colon ( 16 ). Additionally, GLP-1 ...
Both endogenous signaling and pharmacological activation of GLP -1R impact local and systemic inflammation, the gut microbiota, whole-body metabolism, as well as the control of GLP-1 bioavailability.
Roles of glucagon

Such details provide a deeper understanding and appreciation for Glp 1 And Gut Inflammatory Response.
Glucagon-like peptide-1 ( GLP-1 ) is a gut -derived hormone essential for maintaining glucose homeostasis through multiple physiological pathways: triggering insulin release, inhibiting glucagon secretion, delaying gastric emptying, enhancing feelings of fullness, and suppressing appetite. Since GLP-1 is prone to degradation by dipeptidyl peptidase 4, GLP-1 receptor agonists ( GLP -1RAs) have been ...
This review collates current evidence on the microbiome-mediated modulation of GLP-1 dynamics, evaluates the pharmacomicrobiomic impact of GLP-1 agonists and outlines future research directions at the interface of gut microbiota and incretin biology.
While GLP -1RAs ability to lower plasma glucose and to induce weight loss has allowed them to be approved for the treatment of diabetes and obesity, consistent evidences from in vitro studies and preclinical models suggested that GLP -1RAs have anti- inflammatory properties and that may modulate the immune-system.
This review synthesizes basic science and translational evidence supporting glucagon-like peptide-1, glucagon-like peptide-2, and dipeptidyl peptidase-IV inhibition as emerging therapeutic concepts in inflammatory bowel disease.